Everything below concerns research compound. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
=== Osteoclast === Osteoclasts are very large multinucleate cells that are responsible for the breakdown of bones by the process of bone resorption. New bone is then formed by the osteoblasts. Bone is constantly remodeled by the resorption of osteoclasts and created by osteoblasts. Osteoclasts are large cells with multiple nuclei located on bone surfaces in what are called Howship's lacunae (or resorption pits). These lacunae are the result of surrounding bone tissue that has been reabsorbed. Because the osteoclasts are derived from a monocyte stem-cell lineage, they are equipped with phagocytic-like mechanisms similar to circulating macrophages. Osteoclasts mature and/or migrate to discrete bone surfaces. Upon arrival, active enzymes, such as tartrate-resistant acid phosphatase, are secreted against the mineral substrate. The reabsorption of bone by osteoclasts also plays a role in calcium homeostasis.
== Development == Valve entered the VR space in the mid-2010s, demonstrating the Robot Repair VR demo at the 2015 Game Developers Conference. The following year, they partnered with HTC and released the HTC Vive, along with a series of "experiments" called The Lab. Plans to develop a new Half-Life game began after this, and Valve started a project named "The Prototype", helmed by Robin Walker. Concerned that other companies would limit the scope of VR technology, Walker felt that Valve had a duty as a game developer to get involved. Onboarding others in Hawaii opened up two more projects alongside the Index, those being the A.R.T.I. project and SimTrek. These plans ultimately fell through. Walker envisioned a controller that allowed for hand tracking, rather than just functioning as a remote control. The newly focused project developed a slimmed down headset and controllers, named the "Knuckles", that allowed for "believable" hands whilst in VR. Development kits for the Knuckles, codenamed "EV2", were showcased in 2018. Design elements, such as the large trackpad, were adapted from the HTC Vive controllers. These were later toned down, with a thumbstick implemented and a "track button", which is a tracking surface that sat between the stock and now centralised buttons. Hand sizes were considered so that the 5th to 95th percentiles would not have issues holding the Knuckles. Extra size customisations were included, as was a strap.
Biological psychiatry Community psychiatry Cross-cultural psychiatry Emergency psychiatry Evolutionary psychiatry Global mental health Learning disabilities Military psychiatry Neurodevelopmental disorders Neuropsychiatry Interventional Psychiatry Social psychiatry Addiction psychiatry focuses on evaluation and treatment of individuals with alcohol, drug, or other substance-related disorders, and of individuals with dual diagnosis of substance-related and other psychiatric disorders. Biological psychiatry is an approach to psychiatry that aims to understand mental disorders in terms of the biological function of the nervous system. Child and adolescent psychiatry is the branch of psychiatry that specializes in work with children, teenagers, and their families. Community psychiatry is an approach that reflects an inclusive public health perspective and is practiced in community mental health services. Cross-cultural psychiatry is a branch of psychiatry concerned with the cultural and ethnic context of mental disorder and psychiatric services. Emergency psychiatry is the clinical application of psychiatry in emergency settings. Forensic psychiatry utilizes medical science generally, and psychiatric knowledge and assessment methods in particular, to help answer legal questions. Geriatric psychiatry is a branch of psychiatry dealing with the study, prevention, and treatment of mental disorders in the elderly.
Besides their role in photogrammetry, aerial and satellite imagery can be used to identify and delineate terrain features and more general land-cover features. Certainly they have become more and more a part of geovisualization, whether maps or GIS systems. False-color and non-visible spectra imaging can also help determine the lie of the land by delineating vegetation and other land-use information more clearly. Images can be in visible colours and in other spectra.
Sources: en.wikipedia.org
PA 6/66: [NH−(CH2)6−NH−CO−(CH2)4−CO]n−[NH−(CH2)5−CO]m made from caprolactam, hexamethylenediamine and adipic acid; PA 66/610: [NH−(CH2)6−NH−CO−(CH2)4−CO]n−[NH−(CH2)6−NH−CO−(CH2)8−CO]m made from hexamethylenediamine, adipic acid and sebacic acid. The term polyphthalamide (abbreviated to PPA) is used when 60% or more moles of the carboxylic acid portion of the repeating unit in the polymer chain is composed of a combination of terephthalic acid (TPA) and isophthalic acid (IPA).
=== Gram-positive bacteria and eukaryotes === In contrast, in Gram-positive bacteria (e.g. Bacillus stearothermophilus) and eukaryotes the central PDC core contains 60 E2 molecules arranged into an icosahedron. In Eukaryotes, this E2 core coordinates to 30 copies of E1 and 12 copies of E3. Eukaryotes also contain 12 copies of an additional core protein, E3 binding protein (E3BP) which bind the E3 subunits to the E2 core. The exact location of E3BP is not completely clear. Cryo-electron microscopy has established that E3BP binds to each of the icosahedral faces in yeast. However, it has been suggested that it replaces an equivalent number of E2 molecules in the bovine PDC core. Up to 60 E1 or E3 molecules can associate with the E2 core from Gram-positive bacteria - binding is mutually exclusive.
== Sensitivity == It has been shown that PMCA is capable of detecting as little as a single molecule of oligomeric infectious PrPSc. PMCA possesses the ability to generate millions infectious units, starting with the equivalent to one PrPSc oligomer; well below the infectivity threshold. This data demonstrates that PMCA has a similar power of amplification as PCR techniques used to amplify DNA. It opens a great promise for development of a highly sensitive detection of PrPSc, and for understanding the molecular basis of prion replication. Indeed, PMCA has been used by various groups to detect PrPSc in blood of animals experimentally infected with prions during both the symptomatic and pre-symptomatic phases as well as in urine.
=== Legal history === In 1997, three men from the Chicago area sued Hooters after being denied employment at an Orland Park, Illinois, restaurant. Each of them was awarded $19,100. Four men who filed a similar lawsuit in Maryland received $10,350 each. The settlement allows Hooters to continue gender-restricted hiring in its wait staff; the chain agreed to create other support jobs, like bartenders and hosts, that must be filled without regard to gender. In 2000, a federal jury ordered Hooters to pay $275,000 to former waitress Sara Steinhoff, who claimed in her lawsuit that she was the target of unwanted sexual advances, demeaning behavior and recrimination from managers while she worked at the Hooters in Newport, Kentucky, between October 1996 and October 1997. In 2001, a jury determined Hooters of Augusta Inc. willfully violated the Telephone Consumer Protection Act by sending unsolicited advertising faxes. The class-action lawsuit, brought in June 1995 by Sam Nicholson, included 1,320 others who said they received the advertising faxes from Hooters. Atlanta-based Hooters of America Inc., the local restaurant's parent company, paid out $11 million. The jury determined that six faxes were sent to each plaintiff. With a $500 fine for each, that amounts to a $3,000 award per plaintiff. Also in 2001, Jodee Berry, a waitress at a Hooters in Panama City Beach, Florida, won a beer sales contest, for which the promised prize was a new Toyota automobile. However, the manager awarded her a "toy Yoda" instead, claiming the contest was an April Fool's Day joke.
Zalsupindole, also known by its code names DLX-001 and AAZ-A-154 and as (R)-5-methoxy-N,N-dimethyl-α-methylisotryptamine ((R)-5-MeO-α-Me-isoDMT), is non-hallucinogenic serotonin receptor agonist and psychoplastogen of the isotryptamine family related to psychedelic tryptamines such as dimethyltryptamine (DMT). It is under development for the treatment of major depressive disorder and other central nervous system disorders. The drug is taken orally. It acts as a partial agonist of the serotonin 5-HT2A receptor and also interacts with other serotonin receptors. The drug activates the serotonin 5-HT2A receptor with sufficiently high efficacy to promote neuroplasticity but not with adequate efficacy to cause psychedelic effects. It does not produce psychedelic-like effects in animals or humans but does produce antidepressant-like effects in animals. Zalsupindole was first described in the scientific literature by 2021. It was developed by David E. Olson and colleagues at the University of California, Davis and Delix Therapeutics. As of April 2026, it has successfully completed Phase 1 clinical trials, demonstrating positive safety and biomarker data. The FDA has cleared the Investigational New Drug (IND) application for a Phase 2 trial, which includes a study design for at-home administration.
Sources: en.wikipedia.org
Due to the rules, his case could have led to disqualification from the Seoul Olympics and suspension from competition for six months. The levels of the combined stimulants registered in the separate tests were 2 ppm, 4 ppm and 6 ppm. Lewis defended himself, claiming that he had accidentally consumed the banned substances. After the supplements that he had taken were analyzed to prove his claims, the USOC accepted his claim of inadvertent use, since a dietary supplement he ingested was found to contain "Ma huang", the Chinese name for Ephedra (ephedrine is known to help weight-loss). Fellow Santa Monica Track Club teammates Joe DeLoach and Floyd Heard were also found to have the same banned stimulants in their systems, and were cleared to compete for the same reason. The highest level of the stimulants Lewis recorded was 6 ppm, which was regarded as a positive test in 1988 but is now regarded as negative test. The acceptable level has been raised to ten parts per million for ephedrine and twenty-five parts per million for other substances. According to the IOC rules at the time, positive tests with levels lower than 10 ppm were cause of further investigation but not immediate ban.
Xi also gave a speech, saying "As I speak, my compatriots in China are celebrating Mid-Autumn Festival – a cherished occasion for family reunions according to Chinese tradition. I wish you all a very happy Mid-Autumn Festival, and my best wishes to you and your families". He praised Trump and his wife's "meticulous care and consideration" and made them "feel truly at home". He said he and Trump are "making history in our bilateral engagements". He added that "We agreed to build a constructive China-US relationship of strategic stability". He noted that George Washington had an interest in collecting Chinese porcelain. He said "more than 80 years ago, the peoples of China and the U.S. fought side by side against Japanese militarist aggression and pioneered the famous Hump Route". He said "During the war of resistance against Japanese aggression, Chinese soldiers and civilians rescued hundreds of American pilots at the cost of hundreds of thousands of Chinese lives. Such a friendship forged in blood and fire will surely live on through the generations". He said that the friendship was further strengthened by ping-pong diplomacy under President Nixon. He said "Like a river that never stops flowing, history never stands still". He called on the nations to "nurture the beautiful flowers of Sino-US friendship" and that "Together, let us write a new chapter in our friendly relations".
NCI-designated Cancer Centers are a group of 74 cancer research institutions in the United States supported by the National Cancer Institute. Three designations are recognized: Comprehensive Cancer Centers, Clinical Cancer Centers and Basic Laboratory Cancer Centers. As of May 20, 2026, there are 8 Clinical Cancer Centers, 58 Comprehensive Cancer Centers and 8 Basic Laboratory Cancer Centers. Most are associated with a university. Receiving the NCI-designation places cancer centers among the top 4% of the approximately 1,500 cancer centers in the United States. In 2021, more than 411,000 new patients were enrolled in a clinical trial at an NCI-designated Cancer Center.
== Pharmacokinetics == Before clinical testing, a new class of therapeutic agent has to be characterized in terms of preclinical metabolism and excretion studies. Average bioavailability is found to be around 60–65%. Aprepitant is metabolized primarily by CYP3A4 with minor metabolism by CYP1A2 and CYP2C19. Seven metabolites of aprepitant, which are only weakly active, have been identified in human plasma. As a moderate inhibitor of CYP3A4, aprepitant can increase plasma concentrations of co-administered medicinal products that are metabolized through CYP3A4. Specific interaction has been demonstrated with oxycodone, where aprepitant both increased the efficacy and worsened the side effects of oxycodone; however it is unclear whether this is due to CYP3A4 inhibition or through its NK1 antagonist action. Following IV administration of a 14C-labeled prodrug of aprepitant (L-758298), which is converted rapidly and completely to aprepitant, approximately 57% of the total radioactivity is excreted in the urine and 45% in feces. No unchanged substance is excreted in urine.
=== Data logging and compliance === Continuous data logging is fundamental for validation and compliance. This is achieved using standalone temperature data loggers, RFID tags that record temperature, or, most commonly, through the integrated telematics system. This creates an unbroken digital record of a shipment's temperature history from origin to destination, which is the core of a modern track and trace system. This verifiable audit trail is essential for meeting regulatory standards like HACCP and Good Distribution Practice (GDP), and for accurately determining the remaining shelf life of a product.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.